To use all functions of this page, please activate cookies in your browser.
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
26 Current news about the topic migrainerss
|You can refine your search further. Select from the filter options on the left to narrow down your results.|
Addex Pharmaceuticals reported that its lead product, ADX10059, which is nearing completion of Phase IIb testing in gastroesophageal reflux disease (GERD) and migraine prevention, also has demonstrated significant potential in a non-human primate model of Parkinson's disease levodopa induced ...
Addex Pharmaceuticals announced the successful completion of two Phase I studies of a newly developed modified release formulation of ADX48621. The studies showed that ADX48621, a metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator (NAM) in development for Parkinson's ...
Results Demonstrate Safety and Efficacy of First-in-Class Neurally
CoLucid Pharmaceuticals, Inc., announced Phase II results of its lead compound COL-144 in the treatment of acute migraine. Results demonstrated that COL-144 was safe and effective in relieving migraine headaches. COL-144 is a first-in-class Neurally Acting Anti-Migraine Agent (NAAMA), which ...
BTG plc announced that BGC20-1531, a potential treatment for migraine headaches, has commenced clinical development. Dosing has begun in a randomised, double-blind, placebo controlled phase I study, which will assess the safety, tolerability and pharmacokinetic profile of single rising doses of ...
Addex Pharmaceuticals announced that ADX10059 did not reduce acute anticipatory anxiety in a small Phase IIa study in patients with dental anxiety. However, some signs of anxiolytic activity were observed. Development of ADX10059 for gastroesophageal reflux disease (GERD) and migraine is ...
Addex Pharmaceuticals announced the start of the Phase II development programme of its lead compound ADX10059. This announcement follows the successful completion of three Phase I trials, in over 100 healthy subjects, which demonstrated good tolerability of the compound across a broad dose range. ...